Unicycive Therapeutics, Inc. (UNCY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350K 700K 1.1M Q3 '22: 951K Q4 '22: 0 Q1 '23: 675K Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '20: -341K Q2 '20: -336K Q3 '20: -626K Q4 '20: -717K Q1 '21: -731K Q2 '21: -779K Q3 '21: -4.7M Q4 '21: -2.8M Q1 '22: -3.5M Q2 '22: -3.6M Q3 '22: -5.6M Q4 '22: -5.3M Q1 '23: -4.2M Q2 '23: -4.3M Q3 '23: -5.9M Q4 '23: -6.3M Q1 '24: -9.2M Q2 '24: -7.4M Q3 '24: -6.3M Q4 '24: -9.3M Q1 '25: -8M Q2 '25: -7M Q3 '25: -7.3M Q4 '25: -7.2M Q1 '26: -8.4M Q2 '26: -10.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '20: -344K Q2 '20: -338K Q3 '20: -702K Q4 '20: -880K Q1 '21: -964K Q2 '21: -1.1M Q3 '21: -5.2M Q4 '21: -2.8M Q1 '22: -3.5M Q2 '22: -3.6M Q3 '22: -5.6M Q4 '22: -5.3M Q1 '23: -14.6M Q2 '23: -3.8M Q3 '23: -4.3M Q4 '23: -7.8M Q1 '24: -21M Q2 '24: 9.9M Q3 '24: -4.1M Q4 '24: -21.5M Q1 '25: 570K Q2 '25: -6.4M Q3 '25: -6M Q4 '25: -14.7M Q1 '26: -12.8M Q2 '26: -1.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '20: -706K Q4 '20: -538K Q1 '21: -673K Q2 '21: -217K Q3 '21: -3.5M Q4 '21: -1.4M Q1 '22: -3M Q2 '22: -3M Q3 '22: -3.6M Q4 '22: -6.1M Q1 '23: -3.9M Q2 '23: -5.5M Q3 '23: -4.4M Q4 '23: -4.4M Q1 '24: -6.5M Q2 '24: -6.3M Q3 '24: -9.3M Q4 '24: -6.5M Q1 '25: -8.9M Q2 '25: -8.4M Q3 '25: -6M Q4 '25: -8M Q1 '26: -6.2M Q2 '26: -7.6M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q1 '22: -3M Q2 '22: -3M Q3 '22: -3.6M Q4 '22: -6.1M Q3 '23: -4.4M Q4 '23: -4.4M Q1 '24: -6.5M Q2 '24: -6.3M Q3 '24: -9.3M Q4 '24: -6.6M Q1 '25: -8.9M Q2 '25: -8.4M Q3 '25: -6M Q4 '25: -8M Q1 '26: -6.2M Q2 '26: -7.6M Q2 '22 Q4 '22 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 8.6M Q2 '21: 8.8M Q3 '21: 14.2M Q1 '22: 15M Q2 '22: 15M Q3 '22: 15.1M Q1 '23: 15.2M Q2 '23: 15.2M Q3 '23: 32.6M Q1 '24: 34.9M Q2 '24: 9.4M Q3 '24: 8.9M Q1 '25: 12.4M Q2 '25: 12.3M Q3 '25: 18.1M Q1 '26: 23.9M Q2 '26: 26.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '21: -0.78 Q1 '22: -0.91 Q2 '22: -1.02 Q3 '22: -1.02 Q4 '22: -1.20 Q1 '23: -1.93 Q2 '23: -1.98 Q3 '23: -1.74 Q4 '23: -1.55 Q1 '24: -1.19 Q2 '24: -2.40 Q3 '24: -2.73 Q4 '24: -5.21 Q1 '26: -2.21 Q2 '26: -1.75 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.